NCT03525886View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-74788 in Adults With Congenital Adrenal Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

April 10, 2018

Primary Completion Date

April 7, 2020

Study Completion Date

April 7, 2020

Conditions
CAH - Congenital Adrenal Hyperplasia
Interventions
DRUG

NBI-74788

Capsule, administered daily.

Trial Locations (6)

19104

Neurocrine Clinical Site, Philadelphia

46202

Neurocrine Clinical Site, Indianapolis

48109

Neurocrine Clinical Site, Ann Arbor

55454

Neurocrine Clinical Site, Minneapolis

80045

Neurocrine Clinical Site, Aurora

98105

Neurocrine Clinical Site, Seattle

Sponsors
All Listed Sponsors
lead

Neurocrine Biosciences

INDUSTRY